A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

Exclusion Criteria

• •Painful neuropathies or painful conditions other than DPN that may confound evaluation of pain due to DPN during the study.
• •Subjects who have failed previously on pregabalin (at the recommended label dose and for adequate duration) due to lack of efficacy.
• •Subjects with any clinically significant medical or psychiatric conditions or clinically significant laboratory test abnormalities.
• •Pregnant women, lactating mothers, men with partners currently pregnant, women suspected of being pregnant, and women who wish to be pregnant during the course of the clinical study.